SCHEMBL1709756

SCHEMBL1709756

CCCC(=O)Nc1ccc(N)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.72
CA1 P00915 3/20 0.65
CA2 P00918 3/20 0.65
CA12 O43570 2/20 0.65
CA9 Q16790 2/20 0.65
ALDH1A1 P00352 5/20 0.64
MAPT P10636 3/20 0.64
HPGD P15428 3/20 0.64
RAB9A P51151 4/20 0.58
NPC1 O15118 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
THRB P10828 1/20 0.58
HTT P42858 1/20 0.58
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21312154 0.92 TP53 (0.62) TP53CA1CA2CA12CA9
SCHEMBL2281399 0.90 TP53 (0.60) TP53CA1CA2CA12CA9
SCHEMBL2281394 0.90 TP53 (0.60) TP53CA1CA2CA12CA9
SCHEMBL10360235 0.89 CA1 (0.67) TP53CA1CA2CA12CA9
SCHEMBL15197080 0.88 MAPT (0.64) TP53CA1CA2CA12CA9
SCHEMBL7716978 0.87 CA1 (0.68) TP53CA1CA2CA12CA9
SCHEMBL7774872 0.86 CA1 (0.66) CA1CA2CA12CA9ALDH1A1
SCHEMBL3918802 0.86 CA1 (0.66) CA1CA2CA12CA9ALDH1A1
SCHEMBL3919184 0.86 CA1 (0.66) CA1CA2CA12CA9ALDH1A1
SCHEMBL3913717 0.86 CA1 (0.66) CA1CA2CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3146981-A1 COVALENTLY ATTACHED AZOBENZENE SWITCHES AND THEIR USES FOR THE OPTICAL CONTROL OF TARGET PROTEINS Ludwig-Maximilians-Universität München (DE) 2017-03-29 EP disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 WO disclosed
EP-1390343-B1 NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS CHEBIGEN CO LTD (KR) 2009-10-14 EP disclosed
US-7166744-B2 Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds CHEBIGEN CO., LTD. (KR) 2007-01-23 US disclosed
CN-1269799-C Novel retinoid derivatives, process for producing the same and anti-cancer pharmaceutical composition comprising the same CHEBIGEN CO LTD (KR) 2006-08-16 CN disclosed
US-20060110743-A1 Drug evolution: drug design at hot spots KONISHI YASUO 2006-05-25 US disclosed
EP-1390343-A4 NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS CHEBIGEN CO LTD (KR) 2005-06-22 EP disclosed
EP-1390343-A1 NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS Chebigen Co., Ltd. (KR) 2004-02-25 EP disclosed
CN-1455765-A Novel retinoid derivatives and production method thereof and anti-cancer pharmaceutical composition comprising same CHEBIGEN CO LTD (KR) 2003-11-12 CN disclosed
US-20030171339-A1 Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds CHEBIGEN CO., LTD. (KR) 2003-09-11 US disclosed
WO-2002096857-A1 NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS CHEBIGEN CO., LTD. (KR) 2002-12-05 WO disclosed
WO-2002095393-A2 DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2002-11-28 WO disclosed
EP-0198796-B1 MONOAZO DYES, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1990-12-05 EP disclosed
US-4866164-A MONOAZO DYES FOR NATURAL AND SYNTHETIC POLYAMIDES; LIGHTFASTNESS, WETFASTNESS CIBA-GEIGY CORPORATION (US) 1989-09-12 US disclosed
EP-0198796-A2 Monoazo dyes, their preparation and their use CIBA-GEIGY AG (CH) 1986-10-22 EP disclosed
US-4137228-A HIGH TINCTORIAL STRENGTH, COLORFASTNESS CASSELLA AKTIENGESELLSCHAFT (DE) 1979-01-30 US disclosed
US-3971741-A DISPERSION PIGMENTS BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 TP53 118/4885CA1 4308/4885CA2 3413/4885
US-20030171339-A1 Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds RXRB, RARB, RXRA TP53 480/4885CA1 3902/4885CA2 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.